Home/Filings/4/0001562180-19-000094
4//SEC Filing

Strum Jay 4

Accession 0001562180-19-000094

CIK 0001560241other

Filed

Jan 1, 7:00 PM ET

Accepted

Jan 2, 5:46 PM ET

Size

19.5 KB

Accession

0001562180-19-000094

Insider Transaction Report

Form 4
Period: 2019-01-02
Strum Jay
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2019-01-0213,3330 total
    Exercise: $0.39Exp: 2024-01-21Common Stock (13,333 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2019-01-0227,0000 total
    Exercise: $0.39Exp: 2024-07-11Common Stock (27,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2019-01-0215,8160 total
    Exercise: $0.30Exp: 2022-11-09Common Stock (15,816 underlying)
  • Exercise/Conversion

    Common Stock

    2019-01-02$0.30/sh+39,485$11,84688,904 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2019-01-0210,3360 total
    Exercise: $0.30Exp: 2023-01-09Common Stock (10,336 underlying)
  • Exercise/Conversion

    Common Stock

    2019-01-02$0.39/sh+40,333$15,730129,237 total
  • Award

    Stock Option (Right to Buy)

    2019-01-02+15,00015,000 total
    Exercise: $19.56Exp: 2029-01-02Common Stock (15,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2019-01-0213,3330 total
    Exercise: $0.30Exp: 2023-04-16Common Stock (13,333 underlying)
Footnotes (2)
  • [F1]The shares underlying this option vest as to 25% of the shares on January 02, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
  • [F2]All shares underlying this option have vested.

Issuer

G1 Therapeutics, Inc.

CIK 0001560241

Entity typeother

Related Parties

1
  • filerCIK 0001706851

Filing Metadata

Form type
4
Filed
Jan 1, 7:00 PM ET
Accepted
Jan 2, 5:46 PM ET
Size
19.5 KB